Last reviewed · How we verify
Triostat (LIOTHYRONINE)
Triostat works by mimicking the natural thyroid hormone, l-Triiodothyronine, to stimulate the thyroid hormone receptor alpha.
Triostat (Liothyronine) is a small molecule drug developed by King Pharms R&D and currently owned by King Pharms. It targets the thyroid hormone receptor alpha and is classified as a l-Triiodothyronine. Triostat is FDA-approved for various thyroid-related conditions, including congenital hypothyroidism, hypothyroidism, and goiter. The drug is off-patent, with multiple generic manufacturers available. As an off-patent medication, key safety considerations include proper dosing and monitoring to avoid potential side effects.
At a glance
| Generic name | LIOTHYRONINE |
|---|---|
| Sponsor | Pfizer |
| Drug class | l-Triiodothyronine |
| Target | Thyroid hormone receptor alpha |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1956 |
Mechanism of action
Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.
Approved indications
- Congenital hypothyroidism
- Diagnostic Test for Thyroid Dysfunction
- Goiter
- Hypothyroidism
- Malignant tumor of thyroid gland
- Mild Hypothyroidism
- Myxedema
- Myxedema coma
- Simple goiter
- T3 Suppression for Thyroid Function Test
Boxed warnings
- WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including liothyronine sodium tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. Thyroid hormones, including liothyronine sodium tablets, should not be used for the treatment of obesity or for weight loss. Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity ( 6 , 7.7 , 10 ).
Common side effects
- allergic skin reactions
- hyperthyroidism
Drug interactions
- algeldrate
- ferric sulfate
- ferrous gluconate
- iron
- phenprocoumon
- sucralfate
- warfarin
Key clinical trials
- Comparison Of The Effects Of Regional Anesthesia On Brain And Carotid Artery Oxygenation In Shoulder Surgery (NA)
- Internet-based Mindfulness-based Training (iMBT) for People With Depression (NA)
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
- Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer (PHASE2)
- Effect of Physical Activity Program on Sedentary of Patients With Upper Aerodigestive Tract Cancer (NA)
- Paravertebral Block for Mastectomy With Immediate Reconstruction (NA)
- Novel Approaches to the Treatment of Hypothyroidism (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triostat CI brief — competitive landscape report
- Triostat updates RSS · CI watch RSS
- Pfizer portfolio CI